NDANASALSPRAY, METERED
Approved
May 2012
Lifecycle
LOE Approaching
Competitive Pressure
25/100
Clinical Trials
1
Data completeness
7/8 — Comprehensive
DYMISTA (azelastine hydrochloride and fluticasone propionate) by Viatris (2) is propionate; therefore, the mechanisms of actions described below for the individual components apply to dymista. Approved for seasonal allergic rhinitis. First approved in 2012.
Drug data last refreshed 18h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DYMISTA is a fixed-dose nasal spray combining azelastine hydrochloride (H1-receptor antagonist) and fluticasone propionate (synthetic corticosteroid) for seasonal allergic rhinitis. The dual mechanism targets both histamine-mediated symptoms and broad inflammatory pathways, offering rapid symptom relief through complementary antihistamine and corticosteroid activities.
$0.487MPart D
LOE ApproachingDeclining
4mo to LOEProduct is in terminal phase with <5 months of exclusivity remaining; commercial teams should expect significant headcount reductions and transition focus to generic support or portfolio reallocation.
Mechanism of Action
propionate; therefore, the mechanisms of actions described below for the individual components apply to DYMISTA. These drugs represent two different classes of medications (histamine H 1 -receptor antagonist and synthetic corticosteroid). Azelastine Hydrochloride Azelastine hydrochloride, a…
Worked on DYMISTA at Viatris (2)? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.